BASEL, Switzerland, Sept. 22 -- Roche, a biotech company, issued the following news release:

* * *

European Commission approves Roche's Susvimo(R) for the treatment of neovascular age-related macular degeneration (nAMD)

* By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD/1-3

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:

What's your Affiliation

Government Newspaper / Media Business Public Policy Individual / Student Educators

Email:

Phone:

Organization, if any:

State/Country you are in:

Additional questions or comments:

Submit Form Click here for more information about our products